First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i> -Positive Lung CancerAlice T. Shaw, Benjamin Solomon, Julien Mazières et al.|New England Journal of Medicine|2020Cited by 1.1k
Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With <i>ALK</i>-Positive Advanced Non–Small-Cell Lung Cancer From the Phase III CROWN StudyBenjamin Solomon, Tony Mok, Todd M. Bauer et al.|Journal of Clinical Oncology|2022Cited by 133
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial resultsKelly C. Goldsmith, Yaël P. Mossé, Julie R. Park et al.|Nature Medicine|2023Cited by 125